global epidemic [7] . Although the work confirms the promise of a three-gene transcript signature in particular [8] , the feasibility of translation into an affordable, easy-to-use triage test for use in high-burden developing countries remains elusive, given the need for multiplexing and quantitation, based on costs of currently commercialized PCR chemistry and integrated instrumentation. An application as an incipient TB test for high-income countries, however, is becoming more and more realistic. A proteomic approach is more likely to be translated into an affordable triage test, provided that 3 or fewer markers are targeted. However, all published proteomic signatures, including the ones pursued by Scriba and colleagues, require broader validation considering different co-infections, including but not limited to HIV [9] .
When it comes to non-sputum biomarker tests for stand-alone diagnosis, recent publications have demonstrated the potential of Lipoarabinomannan (LAM) for sensitive detection of active TB [10] . The potential impact of these novel, more sensitive tests in the pipeline can be discerned from the work by Huerga and colleagues in this issue showing that the only currently available commercial test targeting LAM, even at highly suboptimal sensitivity, can have a significant impact even outside of patient groups currently recommended by WHO [11] . The value of LAM as a marker for treatment monitoring in sputum is highlighted by Liu and colleagues [12] . Given that both phenotypic and genotypic drug susceptibility testing (DST) is limited for drugs newly recommended for drug-resistant TB (e.g., bedaquiline), improved treatment monitoring tools are becoming even more important.
Advances in treatment of TB in recent years have been limited to multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB [13, 14] , but the treatment of drug-resistant TB still involves regimens with considerable toxicity and shortening the treatment of drugsusceptible TB has been difficult [15] . In this special issue, Savic and colleagues report on meticulous pharmacokinetic and pharmacodynamics evaluations of drug penetration into pulmonary lesions in patients undergoing lung resection, providing important insights into how a number of currently available agents reach or don't reach the site of disease [16] . These observations will be useful in designing and evaluating new regimens, as well as understanding the potential of new agents as they undergo preclinical evaluation.
The limitations of our therapeutic armamentarium are apparent in the unacceptable mortality rate among HIV co-infected patients hospitalized with TB. Gupta-Wright and colleagues describe the development and validation of a simple clinical score, including urine LAM, to identify co-infected patients at higher risk of death both pre-and post-discharge [17] . Yet, even if we could identify these high-risk patients, changing patient outcomes with early and more effective interventions remains a major challenge.
Our therapeutic limitations spotlight the critical need for more effective TB prevention. Recent trials show that shorter, simplified preventive drug regimens are possible [18] . In a Perspective, Churchyard and Swindells discuss the importance of strategies to target latent TB infection in high-risk populations and thus disrupt a reservoir for new infections in high-burden countries [19] . In another Perspective, Vekemans and colleagues discuss some of the recent breakthroughs in the search for an effective TB vaccine [20] . These include positive results from 2 vaccine trials of the subunit vaccine M72/AS01 E and of Bacille Calmette Guerin (BCG) revaccination, which support empirical efficacy testing both for novel vaccine candidates and for existing vaccines using new approaches [21, 22] . One such novel approach is aerosol vaccine delivery to the lung-the site of infection. In this issue, McShane and colleagues describe an experimental medicine trial to explore alternating aerosol and intradermal vaccination routes to boost the immune response to the Mycobacterium tuberculosis antigen 85A [23] . The results highlight the importance of understanding mucosal and systemic immune responses to aerosolized candidate vaccines and the need to optimize tolerability of such vaccination regimens.
Collectively, this special issue highlights the vibrant field of discovery, clinical trials, and implementation research that will enable the End TB targets of the World Health Organization. While there is much promise in new diagnostics, biosignatures, drugs, vaccines, and innovative implementation strategies, this special issue also highlights that, although we have come a long way from Koch, there is a long path still to be walked in order to bend the curve on this ancient disease.
